Attached files

file filename
10-K - FORM 10-K - Eledon Pharmaceuticals, Inc.d832380d10k.htm
EX-23.1 - EX-23.1 - Eledon Pharmaceuticals, Inc.d832380dex231.htm
EX-31.1 - EX-31.1 - Eledon Pharmaceuticals, Inc.d832380dex311.htm
EX-32.1 - EX-32.1 - Eledon Pharmaceuticals, Inc.d832380dex321.htm
EX-31.2 - EX-31.2 - Eledon Pharmaceuticals, Inc.d832380dex312.htm
EX-10.14 - EX-10.14 - Eledon Pharmaceuticals, Inc.d832380dex1014.htm
EX-10.18 - EX-10.18 - Eledon Pharmaceuticals, Inc.d832380dex1018.htm
EX-10.20 - EX-10.20 - Eledon Pharmaceuticals, Inc.d832380dex1020.htm
EX-10.16 - EX-10.16 - Eledon Pharmaceuticals, Inc.d832380dex1016.htm
EX-10.12 - EX-10.12 - Eledon Pharmaceuticals, Inc.d832380dex1012.htm
EX-10.10 - EX-10.10 - Eledon Pharmaceuticals, Inc.d832380dex1010.htm
EXCEL - IDEA: XBRL DOCUMENT - Eledon Pharmaceuticals, Inc.Financial_Report.xls

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Tokai Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Lee H. Kalowski, Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

  (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 26, 2015 /s/ Lee H. Kalowski
Lee H. Kalowski
Chief Financial Officer
(Principal Financial and Accounting Officer)